Shehnaaz Suliman

Shehnaaz Suliman is CEO of ReCode Therapeutics, a genetic medicines company developing mRNA and gene-correcting treatments for cystic fibrosis, certain cancers and other diseases. A physician and experienced drug developer, Dr. Suliman has more than 25 years of experience building pharmaceutical companies.

Prior to her role at ReCode, Dr. Suliman served as President and COO of Alector, a leading immuno-neurology and immuno-oncology company where she played a critical role growing, scaling, raising capital and advancing a late-stage development pipeline. Previously, she served in leadership roles at Theravance Biopharma, Roche, Genentech and Gilead Sciences. Earlier in her career, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners, advising numerous public and private companies on buy- and sell-side transactions.

Dr. Suliman was named to Forbes' 50 Over 50 list; was recognized as one of Fierce Pharma's Fiercest Women in Life Sciences in 2017; and was honored as one of the National Diversity Council’s Power 50 in 2021 (Most Influential Women in Business). She serves as an independent director on the Board of Directors of Ultragenyx Pharmaceutical Inc. and 10x Genomics.

Dr. Suliman received her M.D. (MB, ChB) from the University of Cape Town Medical School, South Africa, and holds an MBA, with distinction, and M.Phil. degrees from Oxford University, where she was a Rhodes Scholar.